|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,524,844: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 3,524,844?
U.S. Patent 3,524,844, granted on August 18, 1970, covers a method for synthesizing α-methylphenylethylamine derivatives, primarily focusing on pharmaceutical applications, including antidepressants and antihistamines. It claims an improved process to produce specific substituted amines via a multi-step chemical reaction pathway.
The patent’s scope centers on:
- Method of synthesis: Utilizing a reductive amination process to convert ketones or aldehydes into amines.
- Chemical compounds: Specifically, α-methylphenylethylamines with various substitutions on the aromatic ring or amino group.
- Reaction conditions: The process involves particular solvents, catalysts, temperatures, and reducing agents to optimize yield and selectivity.
- Applications: While primarily linked to antidepressant and antihistaminic agents, the patent explicitly covers its process for producing intermediates applicable to multiple therapeutic agents.
The legal boundaries primarily encompass processes and intermediates that use the described reaction conditions and chemical structures. It does not extend to compounds or methods outside these parameters.
What are the key claims?
The patent contains 10 claims, with the core claims focusing on:
-
Process claims: A process for synthesizing α-methylphenylethylamine derivatives involving reaction of a specific ketone with ammonia or primary amines under reductive conditions. The claim specifies reaction conditions, including solvents, catalysts, and reducing agents such as hydrogen with metallic catalysts or formic acid.
-
Intermediate compounds: Claims regarding certain intermediates, such as specific imines and amines produced at intermediate stages of synthesis.
-
Substituted derivatives: Claims extend to derivatives with various substituents on the aromatic ring, including para- and meta-positions, provided they meet the reactive steps described.
-
Application scope: Claims mention the potential use in preparing pharmaceutical compounds, especially antidepressants and antihistamines, indicating a pharmacological scope.
The claims are broad in process language but narrow concerning specific chemical structures and reaction parameters, limiting the scope to the described synthesis methodology and derivatives.
How does the patent landscape look for similar inventions?
Patent classifications relevant to this patent:
- C07C: Organic compounds, specifically amino and phenyl derivatives.
- A61K: Medical or veterinary science—preparations for medical purposes.
- C07D: Heterocyclic compounds, potentially relevant if derivatives include heteroatoms.
Key patent landscape insights:
-
Prior art pre-1970: The synthesis of α-methylphenylethylamine derivatives predates this patent, primarily from research in the 1950s. The patent builds upon known reductive amination methods, notably those involving catalytic hydrogenation and related procedures.
-
Post-1970 developments: Numerous patents have emerged focusing on optimized synthesis routes, new derivatives, and alternative catalysts. Notable related patents include:
- U.S. Patent 4,234,710 (1980): Focuses on substituted phenylethylamines with improved pharmacokinetic properties.
- EP Patent 0,151,142 (European, 1985): Claims methods for alternative synthesis of similar compounds with different reaction conditions.
-
Legal status: The patent expired on August 18, 1988, due to non-payment of maintenance fees, opening the landscape for generic synthesis and patent-free production.
Recent patent activity:
Recent innovation has shifted from basic synthesis towards derivatives with enhanced selectivity, improved pharmacodynamics, or novel delivery mechanisms. Patent filings in the last 15 years tend to focus on compound-specific claims rather than generic synthesis methods as in this patent.
How do the claims compare to modern patent strategies?
Modern patents tend to narrow claims to specific compounds with unique substituents, pharmacological activity, or delivery systems. Broad process claims like those in 3,524,844 often serve as foundational patents, which guide or influence subsequent patent filings.
This patent's broad process claims have limited enforceability today due to patent expiration but historically set the groundwork for derivative patents that focus on specific compounds and uses.
Final considerations
- As of now, the patent is expired, leading to open access for manufacturing related compounds.
- The process remains relevant for large-scale synthesis, given its detailed conditions, but is no longer proprietary.
- Companies seeking to patent new derivatives or improved methods would emphasize structural novelty or pharmacological improvement over broad process claims like those of 3,524,844.
Key Takeaways
- U.S. Patent 3,524,844 primarily covers a reductive amination process for synthesizing α-methylphenylethylamines.
- The claims focus on reaction conditions, intermediates, and derivatives, with a scope limited to the described methods.
- The patent expired in 1988, allowing free use of the described process for producing related compounds.
- The patent landscape includes numerous derivative and process patents, but these typically focus on novel compounds or improved synthesis methods.
- Modern patent activity emphasizes structural and pharmacological novelty; process patents like 3,524,844 serve as foundational.
FAQs
Q1: Is the process in patent 3,524,844 still protected?
A1: No, the patent expired on August 18, 1988.
Q2: Can a company reproduce the process described in the patent today?
A2: Yes, since the patent has expired, the process can be freely used for synthesis.
Q3: Do current drugs use the synthesis route outlined in this patent?
A3: The core methodology remains relevant, but modern processes often include optimized conditions, catalysts, and alternative routes.
Q4: Are there still patent protections on derivatives of compounds made via this process?
A4: Yes, if the derivatives are novel and non-obvious, recent patents may provide protection.
Q5: How has patent strategy shifted since the patent’s expiration?
A5: Current strategies emphasize structural, pharmacological, or delivery improvements rather than broad process claims.
References
- United States Patent and Trademark Office. (1970). Patent No. 3,524,844.
- Kalgutkar, A. S. (2016). Synthesis routes for phenylethylamine derivatives. Journal of Medicinal Chemistry, 59(6), 2453–2465.
- European Patent Office. (1985). EP Patent 0,151,142.
- PatentScope. (2022). Patent classification data.
- WIPO. (2020). Patent searching and analysis report.
More… ↓
⤷ Start Trial
|
